ClinicalTrials.gg
Active, not recruitingNCT06229366ACCELUpdated Oct 6, 2026

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

A Phase 1 interventional study of [Ac-225]-PSMA-62 (mCRPC) and [Ac-225]-PSMA-62 (OmHSPC) in Prostate Cancer, Metastatic Castration-resistant Prostate Cancer and Oligometastatic Prostate Carcinoma, sponsored by Eli Lilly and Company. Active, not recruiting at 7 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
142
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Prostatic Neoplasms by Eli Lilly and Company — 2 open to participants now, 8 under way, 3 of them phase 3. Prostatic Neoplasms · Eli Lilly and Company.

Planned enrollment
10th of 19
142 · median 142
Started
2024
with 3 others
Phase 1
7 of 20
2 open now
Registered
17th of 20
by date

Among the 20 studies in Prostatic Neoplasms by Eli Lilly and Company, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 1, and was the 17th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 20 studies in Prostatic Neoplasms by Eli Lilly and Company are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Prostatic Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

ACCEL is a multicenter, open label phase Ia/Ib/II study of [Ac-225]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.

Read the detailed description

The primary aim of the phase Ia study is to evaluate the safety and tolerability of [Ac-225]-PSMA-62 to determine the maximum tolerated dose (MTD). The primary aim of the randomized phase Ib dose optimization is to determine the recommended phase II doses (RP2D) for patients with mCRPC and OmHSPC. The aim of the phase II study for patients with mCRPC is to evaluate the efficacy of [Ac-225]-PSMA-62.

03

Conditions studied

  • Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Oligometastatic Prostate Carcinoma
  • Hormone Sensitive Prostate Cancer

Keywords

  • mCRPC
  • OmHSPC
  • Prostatic Neoplasms
  • Genital Neoplasms, Male
  • Castration Resistant Prostate Cancer
  • Hormone Sensitive Prostate Cancer
  • Oligometastatic Prostate Cancer
  • [225Ac]-PSMA-62
  • Ac-225-PSMA-62
  • Actinium
  • Radioligand Therapy
  • Radiopharmaceuticals
  • Urogenital Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate
  2. performance status 0 to 1
  3. Criteria specific for patients with mCRPC:

    1. Previously received an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy (unless ineligible or refused taxane). Received a maximum of 3 prior systemic therapy regimens in the mCRPC setting
    2. Progressive mCRPC at the time of consent based on at least 1 of the following criteria being met in the context of castrate levels of testosterone:

      • PSA progression defined as rising PSA values at a minimum of 1-week intervals, with the last result being at least 1.0 ng/mL
      • Soft-tissue progression defined as an increase ≥20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions
      • Progression of bone disease defined as the appearance of two or more new lesions by bone scan
    3. At least one PSMA-PET positive lesion for prostate cancer
    4. Castrate circulating testosterone levels (\<1.74 nmol/L or \<50 ng/dL)
  4. Criteria specific for patients with OmHSPC:

    1. PSA recurrence after radical prostatectomy (RP) or definitive radiation therapy (RT), with or without /salvage local therapy (radiation or surgery), with or without (neo)adjuvant ADT

      • PSA ≥ 0.2ng/mL for patients with prior RP +/- RT, or
      • PSA of ≥ 2 ng/mL above nadir for patients with only prior RT
    2. 1- 5 PSMA-PET positive lesions identified outside the prostate bed or remaining gland.

Exclusion criteria

Exclusion Criteria:

  1. Patient has received any other therapeutic agents within 4 weeks or 5 half-lives (whichever is shorter) of starting the study treatment
  2. Evidence of ongoing and untreated urinary tract obstruction
  3. Existing Grade 1 dry mouth (xerostomia) or symptomatic Grade 1 dry eye (xerophthalmia) for any reason
  4. Patient has any concurrent severe and/or uncontrolled medical conditions that could increase the patient's risk for toxicity while on the study or that could confound discrimination between disease- and study treatment-related toxicities
  5. Criteria specific for patients with mCRPC:

    1. Patient has received any PSMA-directed radioligand therapy (e.g., Lu-177-PSMA, Lu-177-PNT2002, Ac-225-J591)
    2. Patient has received any therapeutic systemic radionuclides (e.g., radium-223, rhenium-186, strontium-89), or non-PSMA-directed therapeutic radioligands (e.g., Lu-177-Dotatate) within 5 half-lives of starting the study treatment
  6. Criteria specific for patients with OmHSPC:

    1. Patient has received any systemic anti-cancer therapy for prostate cancer with the exception of (neo)adjuvant ADT for management of localized disease
    2. Presence of any liver
    3. Known presence of central nervous system metastases
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    OmHSPC

    Patients with prostate cancer and biochemical recurrence after definitive surgery or radiation therapy, with 1-5 PSMA-positive lesions, who have not yet initiated lifelong hormone therapy.

    Drug: [Ac-225]-PSMA-62 (OmHSPC)

  • Experimental
    mCRPC

    Patients with PSMA-positive mCRPC who have prior treatment with at least one APRI and received taxane chemotherapy (or ineligible/refused); and received a maximum of 3 prior systemic therapy regimens in the mCRPC setting.

    Drug: [Ac-225]-PSMA-62 (mCRPC)

Interventions

  • Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week cycle for up to 4 cycles. Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week or 4-week cycle, for a total of 4 cycles.

  • Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle for up to 2 cycles. Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle, for a total of 2 cycles.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    Phase Ia: Incidence of dose limiting toxicities (DLTs)

    Time frame: From first dose of study drug through end of DLT period (4 weeks)

  2. Safety, tolerability, and Recommended Phase II Dose (RP2D)

    Phase 1b: Incidence and severity of treatment emergent adverse events (TEAEs)

    Time frame: From first dose of study drug through end of treatment (~16 - 24 weeks)

  3. Safety and tolerability

    Phase Ia: Incidence and severity of treatment emergent adverse events (TEAEs)

    Time frame: From first dose of study drug through end of treatment (~16 - 24 weeks)

Secondary outcomes

  1. The incidence of treatment emergent adverse events as assessed per CTCAE v5.0

    To assess safety and tolerability of \[Ac-225\]-PSMA-62

    Time frame: From first dose of study drug through end of study (~5 years)

  2. Time to initiation of any life-long ADT, or other systemic hormonal therapies for prostate cancer

    OmHSPC only: Preliminary efficacy assessment

    Time frame: From first dose of study drug through end of study (~5 years)

  3. Absorbed dose estimates (Gy) in normal organs

    Evaluation of the biodistribution and radiation dosimetry of \[Ac-225\]-PSMA-62 to normal organs

    Time frame: From first dose of study drug through end of treatment (~16 - 24 weeks)

  4. The proportion of patients with a PSA change from baseline

    To determine the effect of \[Ac-225\]-PSMA-62 on prostate-specific antigen (PSA) kinetics

    Time frame: From first dose of study drug through efficacy follow-up period (up to approximately 3 years)

  5. Objective Response Rate (ORR)

    mCRPC only: Percentage of participants with a complete response (CR) or partial response (PR)

    Time frame: From first dose of study drug until disease progression (up to approximately 3 years)

  6. Radiographic progression free survival (rPFS)

    Phase Ib mCRPC only: rPFS per investigator assessment

    Time frame: From first dose of study drug until disease progression (up to approximately 3 years)

  7. Patient Reported Outcome (PRO) - Pain

    Phase Ib only: Measured by the change on the Brief Pain Inventory Short Form (BPI-SF) questionnaire, scored from 0 ('No pain', 'Does not interfere') to 10 ('Pain as bad as you can imagine', 'Completely interferes') on the severity and interference on daily functions of pain.

    Time frame: From first dose of study drug until disease progression (up to approximately 3 years)

  8. Patient Reported Outcome (PRO) - Impact of treatment toxicity

    Phase Ib only: Measured by the change the Functional Assessment of Cancer Therapy (FACT-Item GP5) questionnaire, scored from 0 ('Not at all') to 4 ('Very much') on the interference of symptoms related to treatment emergent adverse events.

    Time frame: From first dose of study drug until disease progression (up to approximately 3 years)

07

Study locations

7 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Sep 2027, 41 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 41 months is above that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2024
First posted
Jan 29, 2024
StartActual
Apr 3, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2032
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06229366
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Apr 3, 2024
Primary completion
Sep 2027 (estimated)
Completion
Dec 2032 (estimated)
Last update
Oct 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Actinium-225

Start the discussion